|Bid||11.50 x 1300|
|Ask||11.77 x 1000|
|Day's range||11.48 - 12.30|
|52-week range||8.23 - 34.50|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Earnings date||08 Aug 2022 - 12 Aug 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||38.00|
Contrarian investing is fun because when you nail a contrarian pick correctly, you get the joy of saying "I told you so!" Seeing the value in opportunities that other investors discard means capturing outsized profits when things go right. Nano-X's product in development is the Nanox.ARC, an X-ray imaging device that's significantly less expensive to operate than traditional X-ray machines used in hospitals worldwide thanks to its innovative low-cost X-ray tubes. The idea is that when paired with the company's artificial intelligence (AI) software package, remote clinics in economically disadvantaged areas that might not have enough money for an X-ray machine or a radiologist can use the Nanox.ARC and pay Nano-X for each scan they perform.
Earlier today, NANO-X IMAGING LTD. released financial results for the quarter ended March 31, 2022. Erez Meltzer, chief executive officer, and Ran Daniel, chief financial officer, will host this afternoon's call.
NEVE ILAN, Israel, May 19, 2022--Nanox Announces its First Quarter of 2022 Financial Results and Provides Business Update